Table 3.
UVA of explored covariates with survival
| Variable | OS | PFS | |||
|---|---|---|---|---|---|
| HR (CI) | P‐value | HR (CI) | P‐value | ||
| ECOG PS | 0‐1 (n = 59) | 0.28 (0.12‐0.69) | .005 * | 0.34 (0.15‐0.76) | .009 * |
| 2‐3 (n = 8) | — | — | — | — | |
| Number of metastatic sites | 0‐1 (n = 27) | 0.41 (0.16‐1.02) | .055 | 0.49 (0.23‐1.04) | .064 |
| 2 (n = 24) | 1.22 (0.55‐2.72) | .628 | 0.99 (0.50‐1.98) | .980 | |
| 3‐5 (n = 16) | — | — | — | — | |
| Prior lines of therapy | 0‐1 (n = 39) | 1.34 (0.57‐3.13) | .504 | 0.94 (0.47‐1.89) | .871 |
| 2 (n = 14) | 0.99 (0.35‐2.83) | .983 | 0.67 (0.28‐1.62) | .373 | |
| 3‐6 (n = 14) | — | — | — | — | |
| Sites of metastasis | No lymph mets (n = 18) | 0.94 (0.45‐1.95) | .873 | 0.70 (0.36‐1.37) | .296 |
| Lymph mets (n = 49) | — | — | — | — | |
| No bone mets (n = 47) | 0.38 (0.19‐0.73) | .004 * | 0.46 (0.25‐0.82) | .009 * | |
| Bone mets (n = 20) | — | — | — | — | |
| No liver mets (n = 53) | 0.41 (0.20‐0.85) | .017 * | 0.56 (0.29‐1.11) | .096 | |
| Liver mets (n = 14) | — | — | — | — | |
| No brain mets (n = 66) | 0.67 (0.09‐4.94) | .696 | 1.36 (0.19‐9.87) | .762 | |
| Brain mets (n = 1) | — | — | — | — | |
| No lung mets (n = 46) | 1.08 (0.53‐2.19) | .825 | 0.93 (0.51‐1.68) | .803 | |
| Lung mets (n = 21) | — | — | — | — | |
| Baseline albumin | ≥3.9 g/dL (n = 46) | 0.23 (0.11‐0.46) | <.001 * | 0.36 (0.20‐0.65) | <.001 |
| <3.9 g/dL (n = 21) | — | — | — | — | |
| Baseline Hgb | ≥10 g/dL (n = 53) | 0.45 (0.22‐0.93) | .030 * | 0.54 (0.28‐1.02) | .057 |
| <10 g/dL (n = 14) | — | — | — | — | |
| Baseline BMI | <25 (n = 27) | 1.19 (0.62‐2.31) | .603 | 1.05 (0.59‐1.85) | .873 |
| ≥25 (n = 40) | — | — | — | — | |
| Sex | Female (n = 14) | 0.91 (0.40‐2.07) | .816 | 0.93 (0.47‐1.87) | .849 |
| Male (n = 53) | — | — | — | — | |
| Baseline PLR at optimal cut (301.87) | Below (n = 49) | 0.30 (0.15‐0.58) | <.001 * | 0.45 (0.24‐0.81) | .008 * |
| Above (n = 18) | — | — | — | — | |
| Baseline NLR at optimal cut (4.66) | Below (n = 38) | 0.29 (0.15‐0.58) | <.001 * | 0.52 (0.30‐0.91) | .023 * |
| Above (n = 29) | — | — | — | — | |
| Baseline MLR at optimal cut (0.55) | Below (n = 33) | 0.40 (0.20‐0.79) | .008 * | 0.64 (0.37‐1.13) | .128 |
| Above (n = 34) | — | — | — | — | |
Bold values are statistically significant with α < 0.05.
Abbreviations: BMI, body mass index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; Hgb, hemoglobin; HR, hazard ratio; Mets, metastasis; MLR, monocyte‐to‐lymphocyte ratio; NLR, neutrophil‐to‐lymphocyte ratio; OS, overall survival; PFS, progression free survival; PLR, platelet‐to‐lymphocyte ratio; UVA, univariable analysis.
*
Statistical significance at α < 0.05.